Results of a trial with topotecan dose escalation and concurrent thoracic radiation therapy for locally advanced, inoperable nonsmall cell lung cancer

International Journal of Radiation Oncology Biology Physics

Volumn 36, Issue 5, 1996, Pages 1215-1220

  Graham, Mary V ^a   Jahanzeb, Mohammad ^b   Dresler, Carolyn M ^c   Cooper, Joel D ^b   Emami, Bahman ^a   Mortimer, Joanne E ^b  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b WASHINGTON UNIVERSITY   (United States)

^c FOX CHASE CANCER CENTER   (United States)

Author keywords

Lung cancer; Radiation therapy; Topotecan

Indexed keywords

DNA TOPOISOMERASE; SINGLE STRANDED DNA; TOPOTECAN;

ADULT; ADVANCED CANCER; AGED; ANOREXIA; ARTICLE; CANCER RADIOTHERAPY; CLINICAL ARTICLE; DNA STRAND BREAKAGE; DOSE RESPONSE; ESOPHAGITIS; FATIGUE; FEMALE; HUMAN; LUNG NON SMALL CELL CANCER; MALE; NAUSEA; NEUTROPENIA; PRIORITY JOURNAL; RADIATION DOSE; RNA TRANSCRIPTION; TUMOR DIAGNOSIS;

AGED; ANTINEOPLASTIC AGENTS; CAMPTOTHECIN; CARCINOMA, NON-SMALL-CELL LUNG; COMBINED MODALITY THERAPY; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; THORAX; TOPOTECAN;

EID: 0030471360     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0360-3016(96)00367-7     Document Type: Article

References (26)

1. 1. American Joint Committee on Cancer. Manual for staging of cancer, 4th ed. Philadelphia, PA: J. B. Lippincott Co.; 1992:115.
2. 2. Arriagada, R.; LeChevalier, T.; Quoix, E.; Ruffie, P.; de Cremoux, H.; Douillard, Y.-Y.; Tarayre, M.; Pignon, J.-P.; Laplanche, A.; GETCB, F.; C. ASTRO plenary. Effect of chemotherapy on locally advanced nonsmall cell lung carcinoma: A randomized study of 353 patients. Int. J. Radiat. Oncol. Biol. Phys. 20:1183-1190; 1991.
3. 3. Blanke, C.; Ansari, R.; Mantravadi, R.; Gonin, R.; Tokars, R.; Fisher, W.; Pennington, K.; O'Connor, T.; Rynard, S.; Miller, M.; Einhorn, L. Phase III trial of thoracic irradiation with or without Cisplatin for locally advanced unresectable nonsmall-cell lung cancer: A Hoosier Oncology Group Protocol. J. Clin. Oncol. 13:1425-1429; 1995.
4. 4. Bunn, P. A.; Crowley, J.; Kelly, K.; Hazuka, M. B.; Beasley, K.; Upchurch, C.; Livingston, R. Chemoradiotherapy with or without granulocyte-macrophage colony-stimulating factor in the treatment of limited-stage small-cell lung cancer: A prospective Phase III randomized study of the Southwest Oncology Group. J. Clin. Oncol. 13:1632-1641; 1995.
5. 5. Choi, N. C. H.; Doucette, J. A. Improved survival of patients with unresectable nonsmall cell bronchogenic carcinoma by an innovated high-dose en-bloc radiotherapeutic approach. Cancer 48:101-109; 1981.
6. 6. Cox, J. D.; Azarnia, N.; Byhardt, R. W.; Skin, K. H.; Emami, B.; Pajak, T. F. A randomized Phase I/II trial of hyperfractionated radiation therapy with total doses of 60.0 Gy to 79.2 Gy: Possible survival benefit with >69.6 Gy in favorable patients with Radiation Therapy Oncology Group Stage III nonsmall-cell lung carcinoma: Report of Radiation Therapy Oncology Group 83-11. J. Clin. Oncol. 8:1543-1555; 1990.
7. 7. Crino, L.; Meacci, M.; Corgna, E.; et al. Long term results in a locally advanced inoperable nonsmall cell lung cancer (NSCLCA): A randomized trial of induction chemotherapy (CT) plus radiotherapy (RT) vs. radiation alone. Lung Cancer 7:161; 1991.
8. 8. Dillman, R. O.; Seagren, S. L.; Propert, K. J.; Guerra, J.; Eaton, W. L.; Perry, M. D.; Carey, R. W.; Frei, D. F.; Green, M. R. A randomized trial of induction chemotherapy plus high-dose radiation vs. radiation alone in Stage III nonsmall cell lung cancer. N. Engl. J. Med. 323:940-945; 1990.
9. 9. Kim, J. H.; Kim, S. H.; Kolozsvary, A.; Khil, M. S. Potentiation of radiation response in human carcinoma cells in vitro and murine fibrosarcoma in vivo by Topotecan and inhibitor of DNA topoisomerase I. Int. J. Radiat. Oncol. Biol. Phys. 22:515-518; 1992.
10. 10. LeChevalier, T.; Arriagada, R.; Quoix, E.; Ruffie, P.; Martin, M.; Tarayre, M.; Lacome-Terrier, M. J.; Douillar, J. Y.; Laplanche, A. Radiotherapy alone vs. combined chemotherapy and radiotherapy in nonresectable nonsmall cell lung cancer: First analysis of a randomized trial in 353 patients. J. Natl. Cancer Inst. 83:417-423; 1991.
11. 11. Lilenbraun, R. C.; Green, M. R. Novel chemotherapeutic agents in the treatment of nonsmall cell lung cancer. J. Clin. Oncol. 11:1391-1402; 1993.
12. 12. Lynch, T. J.; Kalish, L.; Strauss, G.; Elias, A.; Skarin, A.; Shulman, L. N.; Posner, M.; Frei, E., III. Phase II study of Topotecan in metastatic nonsmall cell lung cancer. J. Clin. Oncol. 12:347-352; 1994.
13. 13. Mattern, M. R.; Hofmann, G. A.; McCable, F. L.; Johnson, R. K. Synergistic cell killing by ionizing radiation and topoisomerase I inhibitor Topotecan (SK&F 104864). Cancer Res. 51:5813-5816; 1991.
14. 14. Mattson, K.; Holsti, L. R.; Holsti, P.; Jakobsson, M.; Kajanti, M.; Liippo, K.; Mantyla, M.; Nittamo-Korhonen, S.; Nikkanen, V.; Nordman, E.; et al. Inoperable nonsmall cell lung cancer: Radiation with or without chemotherapy. Eur. J. Cancer Clin. Oncol. 24:477-482; 1988.
15. 15. Miller, A. A.; Hargis, J. B.; Lilenbaum, R. C.; Fields, S. Z.; Rosner, G. L.; Schilsky, R. L. Phase I study of Topotecan and Cisplatin in patients with advanced solid tumors: A Cancer and Leukemia Group B Study. J. Clin. Oncol. 12:2743-2750; 1994.
16. 16. Mountain, C. F. A method for the assessment of operation in the control of lung cancer. Ann. Thorac. Surg. 24:365-373; 1977.
17. 17. Naroke, T.; Suemasu, K.; Ishikawa, S. Lymph node mapping and comorbidity at various levels of metastasis in resected lung cancer. J. Thorac. Cardiovasc. Surg. 76:832-839; 1978.
18. 18. PAACR 33. No. 2609: March 1992.
19. 19. Perez, C. A.; Stanley, K.; Rubin, P. Patterns of tumor recurrence after definitive irradiation for inoperable nonoat cell carcinoma of the lung. Int. J. Radiat. Oncol. Biol. Phys. 6:987-994; 1980.
20. 20. Recondo, G.; Abbruzzese, J.; Newman, B.; Newman, R.; Kuhn, J.; Von Hoff, D.; Garteiz, D.; Raber, M. A Phase I trial of Topotecan (TOPO) administered by a 24-hour infusion. Proc. Am. Assoc. Cancer Res. 32:1229A; 1991.
21. 21. Sause, W.; Scott, C.; Taylor, S.; Johnson, D.; Livingston, R.; Komaki, R.; Emami, B.; Curran, W.; Byhardt, R.; Fisher, B.; Turrisi, A. RTOG 8808 ECOG 4588, Preliminary analysis of a Phase II trial in regionally advanced unresectable nonsmall cell lung cancer. Am. J. Clin. Oncol. 13:325; 1994.
22. 22. Schaake-Koning, C.; Van den Bogaert, W.; Dalesio, O.; Festen, J.; Hoogenhout, J.; van Houtte, P.; Kirkpatrick, A.; Koolen, M.; Maat, B.; Nijs, A.; Renaud, A.; Rodrigus, P.; Schuster-Uitterhoeve, L.; Sculier, J.; van Zandwijk, N.; Bartelink, H. Radiotherapy combined with low-dose cisplatin; Results of the EORTC 08844 Phase III study by the EORTC Radiotherapy and Lung Cancer Cooperative Groups. Lung Cancer 9:245-248; 1993.
23. 23. Schaake-Koning, C.; van den Bogaert, W.; Dalesio, O.; Festen, J.; Hoogenhout, J.; van Houtte, P.; Kirkpatrick, A.; Koolen, M.; Maat, B.; Nijs, A.; Renaud, A.; Rodrigus, P.; Schuster-Uitterhoeve, L.; Sculier, J. P.; van Zandwijk, N.; Bartelink, H. Effects of concomitant cisplatin and radiotherapy on inoperable nonsmall-cell lung cancer. N. Engl. J. Med. 326:524-530; 1992.
24. 24. Schiller, J. H.; Kim, K.; Johnson, D. Phase II study of topotecan in extensive stage small cell lung cancer. Am. Soc. Clin. Oncol. 1:330; 1994.
25. 25. Trovo, M. G.; Minatel, E.; Franchin, G.; et al. Radiotherapy (RT) vs. RT enhanced by cisplatin (DDP) in Stage III nonsmall cell lung cancer (NSCLCA): A randomized cooperative study. Lung Cancer 7:158; 1991.
26. 26. Wall, J.; Burris, H.; Rodriguez, G.; Brown, T.; Weiss, G.; Kuhn, J.; Brown, J.; Johnson, R.; Friedman, C.; Mann, W.; Von Hoff, D. Phase I trial of Topotecan (SK&F 104864) in patients with refractory solid tumors. Proc. Am. Soc. Clin. Oncol. 10:261A; 1991.